Fairvalue-Calculator Fairvalue-Calculator
EN DE

ABIONYX Pharma SA (ABNX) Fair Value & Analysis

Healthcare · FR · Market cap €102M

Price€2.22
Fair Value€0.5400
Upside-75.7%
Quality95/100
Evidence: Low Range €0.4000 – €0.6700

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ABIONYX Pharma SA (ABNX) currently trades at €2.22, while our model-based Fair Value estimate is €0.5400 — implying the stock looks roughly 75.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is ABIONYX Pharma SA (ABNX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.5400 versus a price of €2.22 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ABNX?
Our 21-model fair value for ABIONYX Pharma SA is €0.5400 (as of Jun 24, 2026), built from audited fundamentals. The current price is €2.22.
What is the quality score of ABNX?
ABIONYX Pharma SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.